Relmada Therapeutics Stock (NASDAQ:RLMD), Quotes and News Summary

Q: How do I buy Relmada Therapeutics (RLMD) stock?

You can purchase shares of Relmada Therapeutics (NASDAQ: RLMD) through any online brokerage. View our list of the best stock brokerages.

Q: Who are Relmada Therapeutics's (RLMD) competitors?

Other companies in Relmada Therapeutics’s space includes: Zevra Therapeutics (NASDAQ:ZVRA) , Xeris Biopharma Holdings (NASDAQ:XERS) , Rani Therapeutics Hldgs (NASDAQ:RANI) , Marinus Pharma (NASDAQ:MRNS) and Alimera Sciences (NASDAQ:ALIM) .

Q: What is the target price for Relmada Therapeutics (RLMD) stock?

The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by Mizuho on Thursday, June 15, 2023. The analyst firm set a price target for 26.00 expecting RLMD to rise to within 12 months (a possible 611.35% upside). 1 analyst firms have reported ratings in the last year.

Q: Current Stock Price for Relmada Therapeutics (RLMD)?

The stock price for Relmada Therapeutics (NASDAQ: RLMD) is $3.655 last updated Today at April 30, 2024 at 3:56 PM EDT.

Q: Does Relmada Therapeutics (RLMD) pay a dividend?

There are no upcoming dividends for Relmada Therapeutics.

Q: When is Relmada Therapeutics (NASDAQ:RLMD) reporting earnings?

Relmada Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.

Q: Is Relmada Therapeutics (RLMD) going to split?

There is no upcoming split for Relmada Therapeutics.

Q: What sector and industry does Relmada Therapeutics (RLMD) operate in?

Relmada Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Relmada Therapeutics Stock (NASDAQ: RLMD) stock price, news, charts, stock research, profile.

Open	$3.530
Close	-
Volume / Avg.	128.991K / 213.824K
Day Range	3.460 - 3.740
52 Wk Range	2.360 - 7.223
Market Cap	$105.308M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	34
Short Interest	5.71%
Days to Cover	5.93

Recent News

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

Avi Kapoor

Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study

Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Rating

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

About Relmada Therapeutics Inc

Sector

Health Care

Industry

Pharmaceuticals

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chem...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Relmada Therapeutics (RLMD) stock?

You can purchase shares of Relmada Therapeutics (NASDAQ: RLMD) through any online brokerage.

View our list of the best stock brokerages.

Who are Relmada Therapeutics's (RLMD) competitors?

Other companies in Relmada Therapeutics’s space includes: Zevra Therapeutics (NASDAQ:ZVRA), Xeris Biopharma Holdings (NASDAQ:XERS), Rani Therapeutics Hldgs (NASDAQ:RANI), Marinus Pharma (NASDAQ:MRNS) and Alimera Sciences (NASDAQ:ALIM).

What is the target price for Relmada Therapeutics (RLMD) stock?